Business Wire

Svante and Tenaska Forge Collaboration to Deliver Fully Integrated Carbon Capture and Storage Solutions

16.1.2025 15:03:00 CET | Business Wire | Press release

Share

Svante Technologies Inc. (Svante), a leading innovator in carbon capture and removal technology, and Tenaska, a prominent CO2 transportation and sequestration service provider, have signed a Memorandum of Understanding (MOU) to collaborate on delivering cost-effective, integrated solutions for industrial carbon capture and storage (CCS). This collaboration represents a significant step toward addressing global industrial emissions and advancing the decarbonization of many industrial sectors, including pulp & paper, cement, steel, oil & gas, and more.

Under the terms of the non-exclusive MOU, Svante and Tenaska will combine their technology and services to provide end-to-end CCS value chain solutions to select customers. Svante’s cutting-edge solid sorbent-based carbon capture technology will facilitate efficient, environmentally responsible CO2 capture, while Tenaska will provide regional planning and infrastructure for CO2 transportation and storage. Tenaska is advancing a platform of mid- and early-stage projects in strategic locations across the United States, with Class VI permit applications filed for nearly 20 injection wells across multiple states.

Together, the companies aim to simplify the path to decarbonization for industrial emitters worldwide.

Key Objectives of the Collaboration:

  1. Integrated Carbon Management Solutions:
    • Svante will focus on capturing CO2 emissions at industrial facilities, including related processes such as CO2 compression, conditioning, and liquefaction.
    • Tenaska will manage CO2 transportation and sequestration, ensuring safe, secure, permanent storage deep underground.
  2. North America-wide Outreach and Customer Engagement:
    • The joint initiative will actively promote carbon capture and storage to industrial emitters across North America, offering tailored solutions to meet diverse needs.
  3. Innovative Project Development:
    • The collaboration will identify and assess commercially viable opportunities for CCS, leveraging the combined technical and operational expertise of both organizations.

Leadership Quotes:

“This collaboration is well aligned with Svante’s mission to make carbon capture accessible for industries worldwide,” said Matt Stevenson, Chief Revenue Officer of Svante. “By combining our technology with Tenaska’s extensive experience in CO2 transportation and storage, we can offer end-to-end solutions that accelerate the transition to a net-zero future.”

“Recognizing the synergies with our CCS development platform, Tenaska is proud to work with Svante to advance innovative solutions for carbon management,” said Bret Estep, Vice President, Tenaska Development. “Together, we aim to provide industrial customers with the tools and confidence to achieve their decarbonization goals.”

A Vision for the Future

The Svante-Tenaska collaboration underscores a shared commitment to providing business solutions that help industrial sectors reduce carbon emissions. By offering integrated, efficient, and scalable CCS solutions, the companies aim to unlock new opportunities for industries to meet their sustainability targets while maintaining operational excellence.

About Svante

Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on the 2024 Global Cleantech 100, the XPRIZE Foundation’s XB100 – World’s Top 100 Deep Tech Companies and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies. For more information, visit www.svanteinc.com and follow Svante on LinkedIn at www.linkedin.com/svantesolutions.

About Tenaska

Consistently ranked among Forbes’ List of America’s Largest Private Companies, Tenaska is a leading energy company with business operations that span the energy value chain. Tenaska Marketing Ventures (TMV) and Tenaska Power Services Co. (TPS) are among the largest natural gas and electric power marketing companies in North America. The company has an operating fleet of 7,460 megawatts (MW) of natural gas and renewable generating facilities and throughout its history has developed, managed and/or operated approximately 22,000 MW of natural gas-fueled and renewable generation. Tenaska is actively developing 10 carbon sequestration projects capable of storing more than 50 million metric tons of CO2 per year, multiple natural gas-fueled generation projects and a development services portfolio of more than 35,000 MW of solar, wind, energy storage and green hydrogen projects. Tenaska seeks investment opportunities to allocate its capital into generation assets nationwide. For more information, visit www.tenaska.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250116961790/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye